| |
How is your lab navigating complex NGS workflows? In this webinar, hear subject matter experts explore how a lab informatics solution with out-of-the-box NGS capabilities delivers real value. View Now. 
|
|
Today’s Big NewsSep 12, 2023 |
| By Nick Paul Taylor CEO Nick Leschly is leading a long list of 2seventy bio employees who are heading to the exit. With rival drugs putting its approved cell therapy under pressure, the bluebird bio spinout is eliminating 176 roles and advancing fewer R&D programs internally to stretch its cash runway out to 2026. |
|
|
|
| Philadelphia, PA |  |
|
|
By Nick Paul Taylor Acelyrin has given its investors a nasty shock. Months after raising $540 million in a rare biotech IPO, the company has reported the failure of its lead prospect in a phase 2b/3 inflammatory disease clinical trial, causing its share price to plummet by 58% in premarket trading. |
By Annalee Armstrong CureVac has hand-picked the mRNA influenza vaccine that will advance into the phase 2 portion of a clinical trial, but the famously tight-lipped biotech is keeping the data to itself for now. |
Sponsored by IQVIA With IQVIA’s clinical trial solutions and flexible site support strategies, decentralized trial elementss are being leveraged to enhance patient- centered care as well as support sites through hands- on enablement and implementation of DCT platforms these services. |
By James Waldron Only two months after snagging $150 million from investors to take its first G-protein-coupled receptor drug into the clinic, Septerna has added another $47.5 million to the pile courtesy of a licensing deal with Vertex. |
By James Waldron Arbutus Biopharma has become the latest biotech to exit the COVID-19 space as well as discontinuing its work on RNA destabilizers, tightening its focus on hepatitis B. |
By Max Bayer Exelixis is diving into AI drug development in a licensing deal with Insilico, while LIB Therapeutics is cashing in after a second phase 2 victory. |
By James Waldron Neurocrine Biosciences has a lot riding on its hyperplasia drug crinecerfont, which analysts tout as a potential blockbuster. Plus, the company needs a win after throwing in the towel on a Parkinson’s disease med. Luckily, phase 3 data have delivered the goods. |
By Annalee Armstrong Rome wasn’t built in a day, and neither was Rome Therapeutics, which today revealed a series B financing extension of $72 million that includes Big Pharma pillars Johnson & Johnson and Bristol Myers Squibb. |
By Annalee Armstrong Neumora and RayzeBio are both casting a line into the market, with each seeking to raise more than $200 million in initial public offerings this fall. |
By Gabrielle Masson Vigil Neuroscience has been granted clearance from the FDA to launch an early-stage Alzheimer’s trial, but that approval comes with strings attached: a partial clinical hold. |
By Helen Floersh While science is still a long way off from using animals as incubators for human organs—a prospect that's rife with ethical dilemmas—the development marks a milestone for transplant medicine. |
By Fraiser Kansteiner The FDA has approved Pfizer and Moderna’s separate vaccine formulations that target current variants of the disease. Each company’s shot is approved for people ages 12 and up and emergency authorized for patients 6 months old to 11 years old. |
By Andrea Park The FDA has cleared a handful of AR-based technologies that add virtual overlays to a surgeon’s view, highlighting target areas and providing helpful calculations and other analytics on the side. |
By Dave Muoio The largest charitable donation in City of Hope's history will help establish an evidence-based "integrative oncology" program that melds Eastern cultures' healing traditions, such as acupuncture or meditation, with cancer treatments more typical in the West. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
